Article
Cardiac & Cardiovascular Systems
Michael Harris, Junhui Sun, Karen Keeran, Angel Aponte, Komudi Singh, Danielle Springer, Marjan Gucek, Mehdi Pirooznia, Matthew E. Cockman, Elizabeth Murphy, Leslie M. Kennedy
Summary: This study demonstrates that deletion of Ogfod1 alters the myocardial proteome and metabolome, providing protection against ischemia-reperfusion injury.
CARDIOVASCULAR RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Siavash Beikoghli Kalkhoran, Janos Kriston-Vizi, Sauri Hernandez-Resendiz, Gustavo E. Crespo-Avilan, Ayeshah A. Rosdah, Jarmon G. Lees, Joana Rodrigues Simoes Da Costa, Naomi X. Y. Ling, Jessica K. Holien, Parisa Samangouei, Kroekkiat Chinda, En Ping Yap, Jaime A. Riquelme, Robin Ketteler, Derek M. Yellon, Shiang Y. Lim, Derek J. Hausenloy
Summary: Hydralazine provides acute cardioprotection by inhibiting Drp1-mediated mitochondrial fission.
CARDIOVASCULAR RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Ruduwaan Salie, John Lopes, Leon Kotze, Ruzayda van Aarde
Summary: This study investigates the cardioprotective effects of Blue Sage in ischemia-reperfusion injury. The results demonstrate that Blue Sage can activate/inhibit multiple signaling pathways simultaneously and mediate cardioprotection in a multitarget manner.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Hiromasa Yamashita, Masahiro Fujii, Ryuzo Bessho, Yosuke Ishii
Summary: This study confirmed the cardioprotective effect of the pre-ischaemic administration of esaxerenone. Esaxerenone may contribute to coronary endothelial protection and exert pharmacological preconditioning via the mitochondrial KATP channel.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
(2023)
Article
Biochemistry & Molecular Biology
Podsawee Mongkolpathumrat, Anusak Kijtawornrat, Eukote Suwan, Sasimanas Unajak, Aussara Panya, Tonapha Pusadee, Sarawut Kumphune
Summary: The Secretory Leukocyte Protease Inhibitor (SLPI) has been shown to have therapeutic potential in protecting the heart against injury. The study investigated the role of SLPI in cardioprotection and found that a mutant form of SLPI lacking anti-protease activity significantly reduced cell death and reactive oxygen species production in simulated ischemia/reperfusion injury. Additionally, treatment with the mutant SLPI reduced infarct size, improved cardiac function, and decreased markers of injury in rats subjected to in vivo ischemia/reperfusion injury.
Article
Biochemistry & Molecular Biology
Agnieszka Olejnik, Anna Krzywonos-Zawadzka, Marta Banaszkiewicz, Iwona Bil-Lula
Summary: This study found that Klotho protein has a protective effect on cardiomyocytes during ischemia-reperfusion injury by inhibiting matrix metalloproteinase-mediated degradation of contractile proteins.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Kishal Lukhna, Derek J. Hausenloy, Abdelbagi Sidahmed Ali, Abdullah Bajaber, Alistair Calver, Arthur Mutyaba, Awad Abdalla Mohamed, Brian Kiggundu, Chishala Chishala, Ebrahim Variava, Ehab Ali Elmakki, Elijah Ogola, Eltayeb Hamid, Emmy Okello, Isam Gaafar, Keiran Mwazo, Makoali Makotoko, Mergan Naidoo, Mohamed Elhadi Abdelhameed, Motasim Badri, Nasief van der Schyff, Omaima Abozaid, Paul Xafis, Sara Giesz, Trevor Gould, Waldo Welgemoed, Malcolm Walker, Mpiko Ntsekhe, Derek M. Yellon
Summary: Despite evidence of myocardial infarct size reduction in animal studies, remote ischaemic conditioning (RIC) failed to improve clinical outcomes in the large CONDI-2/ERIC-PPCI trial. The RIC-AFRICA trial aims to investigate whether RIC can improve clinical outcomes in higher-risk STEMI patients in environments with limited access to early reperfusion or PPCI.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
David Adlam, Maciej Zarebinski, Neal G. Uren, Pawel Ptaszynski, Keith G. Oldroyd, Shahzad Munir, Azfar Zaman, Hussain Contractor, Robert Gabor Kiss, Istvan Edes, Joanna Szachniewicz, Gergely Gyorgy Nagy, Mario J. Garcia, Janos Tomcsanyi, John Irving, Andrew S. P. Sharp, Piotr Musialek, Geza Lupkovics, Cheerag Shirodaria, Joseph B. Selvanayagam, Pauline Quinn, Leong Ng, Mark Roth, Michael A. Insko, Ben Haber, Stephen Hill, Lori Siegel, Simon Tulloch, Keith M. Channon
Summary: The study showed that giving FDY-5301 prior to PPCI in first-time STEMI patients increased plasma iodide levels and reduced myocardial damage in some patients after infarction, while also being safe and feasible.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Petra Kleinbongard, Helmut Lieder, Andreas Skyschally, Gerd Heusch
Summary: This study compared the infarct size in female, castrated male, and male pigs undergoing ischemia/reperfusion (I/R) and ischemic preconditioning (IPC). The results showed no sex- or castration-related differences in infarct size, coronary microvascular injury, and cardioprotection by IPC.
CARDIOVASCULAR RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Alejandro Ciocci Pardo, Leandro A. Diaz Zegarra, Luisa F. Gonzalez Arbelaez, Ernesto A. Aiello, Susana M. Mosca
Summary: The increase in intracellular calcium concentration caused by influx through L-type calcium channels is a major contributor to ischemia-reperfusion injury, and inhibition of these channels has been shown to ameliorate post-ischemic damage. Recent research has shown that N-methylacetazolamide (NMA), a compound derived from acetazolamide, can protect the heart against ischemia-reperfusion injury and improve post-ischemic recovery. This protection may be due to its inhibitory action on L-type calcium channels.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Neurosciences
Dick H. J. Thijssen, Laween Uthman, Yasina Somani, Niels van Royen
Summary: Regular exercise has potent protective effects against cardiovascular disease. In addition to the long-term benefits, single bouts of exercise can also provide immediate cardioprotection by reducing cardiac and vascular damage caused by ischaemia and reperfusion injury. This immediate protection is mediated through the activation of multiple pathways and can be optimized by considering exercise-related and subject-related factors. Understanding the mechanisms behind immediate cardioprotection can help in developing effective strategies for individuals with (multi-)diseases and age-related conditions.
JOURNAL OF PHYSIOLOGY-LONDON
(2022)
Article
Cardiac & Cardiovascular Systems
Xiao Wang, Ruifeng Guo, Yingying Guo, Qian Guo, Yan Yan, Wei Gong, Wen Zheng, Hui Wang, Lei Xu, Hui Ai, Bin Que, Xiaoyan Yan, Xinliang Ma, Shaoping Nie
Summary: The RESTORE trial aims to evaluate the effect of Shenfu injection on reducing infarct size in STEMI patients undergoing PPCI. The trial will enroll 326 patients who will be randomly assigned to receive either Shenfu injection or placebo. The primary endpoint is the assessment of infarct size by cardiac magnetic resonance imaging 5 days after PPCI.
AMERICAN HEART JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Hai-Jian Sun, Zhi-Yuan Wu, Xiao-Wei Nie, Xin-Yu Wang, Jin-Song Bian
Summary: Cardiovascular diseases are common complications of diabetes, with diabetic cardiomyopathy being a major cause of death in diabetes. Research has found that hydrogen sulfide plays a critical role in diabetic cardiomyopathy and has protective effects in conditions such as myocardial infarction and heart failure under diabetic conditions. Studies have identified multiple molecular mechanisms responsible for H2S's protective effects against diabetes-induced cardiac injury.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Chemistry, Medicinal
Estefanie Osorio-Llanes, Wendy Villamizar-Villamizar, Maria Clara Ospino Guerra, Luis Antonio Diaz-Ariza, Sara Camila Castiblanco-Arroyave, Luz Medrano, Daniela Mengual, Ricardo Belon, Jairo Castellar-Lopez, Yanireth Sepulveda, Cesar Vasquez-Trincado, Aileen Y. Chang, Samir Bolivar, Evelyn Mendoza-Torres
Summary: The search for new drugs to effectively treat cardiovascular diseases is crucial due to their high mortality rate globally. Metformin, commonly used to control diabetes, has shown potential cardioprotective effects by regulating cellular energy metabolism and reducing oxidative stress. Clinical trials have revealed promising results, particularly in acute myocardial infarction cases. This review discusses the molecular and pharmacological mechanisms underlying the cardioprotective effects of metformin during myocardial ischemia-reperfusion injury.
Review
Endocrinology & Metabolism
Guntram Schernthaner, Kerstin Brand, Clifford J. Bailey
Summary: Metformin, a drug used for treating type 2 diabetes, has been replaced to some extent by newer antidiabetic medications. However, research on its potential cardiovascular benefits continues.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Cardiac & Cardiovascular Systems
Diana A. Gorog, Mohamed Farag, Nikolaos Spinthakis, Derek M. Yellon, Hans Erik Botker, Rajesh K. Kharbanda, Derek J. Hausenloy
Summary: The study found that RIC may reduce platelet reactivity in the first 48 hours post-STEMI, but there was no significant difference at 6-8 weeks after discharge. Additionally, RIC had no effect on clot formation or endogenous fibrinolysis in the study. Further research is needed to explore the mechanisms through which RIC may reduce platelet reactivity and improve outcomes in patients with persistent high on-treatment platelet reactivity.
CARDIOVASCULAR RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Siavash Beikoghli Kalkhoran, Janos Kriston-Vizi, Sauri Hernandez-Resendiz, Gustavo E. Crespo-Avilan, Ayeshah A. Rosdah, Jarmon G. Lees, Joana Rodrigues Simoes Da Costa, Naomi X. Y. Ling, Jessica K. Holien, Parisa Samangouei, Kroekkiat Chinda, En Ping Yap, Jaime A. Riquelme, Robin Ketteler, Derek M. Yellon, Shiang Y. Lim, Derek J. Hausenloy
Summary: Hydralazine provides acute cardioprotection by inhibiting Drp1-mediated mitochondrial fission.
CARDIOVASCULAR RESEARCH
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Antonio Cannata, Daniel I. Bromage, Theresa A. McDonagh
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Mohammed Shah, Zhenhe He, Ali Rauf, Siavash B. Kalkhoran, Christina Mathisen Heiestad, Kare-Olav Stenslokken, Christopher R. Parish, Oliver Soehnlein, Sapna Arjun, Sean M. Davidson, Derek Yellon
Summary: This study found that histones released during myocardial infarction are toxic to cardiomyocytes, and this toxicity is independent of TLR4. Inhibiting the release of histones can reduce cardiomyocyte death, providing a new therapeutic opportunity for ischemia-reperfusion injury.
CARDIOVASCULAR RESEARCH
(2022)
Correction
Cardiac & Cardiovascular Systems
Sean M. Davidson, Kishal Lukhna, Diana A. Gorog, Alan D. Salama, Alejandro Rosell Castillo, Sara Giesz, Pelin Golforoush, Siavash Beikoghli Kalkhoran, Sandrine Lecour, Aqeela Imamdin, Helison R. P. do Carmo, Ticiane Goncalez Bovi, Mauricio W. Perroud, Mpiko Ntsekhe, Andrei C. Sposito, Derek M. Yellon
CARDIOVASCULAR DRUGS AND THERAPY
(2022)
Correction
Cell Biology
A. R. Hall, N. Burke, R. K. Dongworth, S. B. Kalkhoran, A. Dyson, J. M. Vicencio, G. W. Dorn, D. M. Yellon, D. J. Hausenloy
CELL DEATH & DISEASE
(2021)
Article
Cardiac & Cardiovascular Systems
Kishal Lukhna, Derek J. Hausenloy, Abdelbagi Sidahmed Ali, Abdullah Bajaber, Alistair Calver, Arthur Mutyaba, Awad Abdalla Mohamed, Brian Kiggundu, Chishala Chishala, Ebrahim Variava, Ehab Ali Elmakki, Elijah Ogola, Eltayeb Hamid, Emmy Okello, Isam Gaafar, Keiran Mwazo, Makoali Makotoko, Mergan Naidoo, Mohamed Elhadi Abdelhameed, Motasim Badri, Nasief van der Schyff, Omaima Abozaid, Paul Xafis, Sara Giesz, Trevor Gould, Waldo Welgemoed, Malcolm Walker, Mpiko Ntsekhe, Derek M. Yellon
Summary: Despite evidence of myocardial infarct size reduction in animal studies, remote ischaemic conditioning (RIC) failed to improve clinical outcomes in the large CONDI-2/ERIC-PPCI trial. The RIC-AFRICA trial aims to investigate whether RIC can improve clinical outcomes in higher-risk STEMI patients in environments with limited access to early reperfusion or PPCI.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Daniel I. Bromage, Silvia C. Trevelin, Josef Huntington, Victoria X. Yang, Ananya Muthukumar, Sarah J. Mackie, Greta Sawyer, Xiaohong Zhang, Celio X. C. Santos, Niloufar Safinia, Ioannis Smyrnias, Mauro Giacca, Aleksandar Ivetic, Ajay M. Shah
Summary: Dysregulated inflammation is implicated in ventricular remodeling and heart failure after myocardial infarction (MI). Transcription factor Nrf2 is a promising target as it inhibits pro-inflammatory cytokines and has anti-inflammatory effects.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Cardiac & Cardiovascular Systems
Thomas R. Godec, Daniel Bromage, Mar Pujades-Rodriguez, Antonio Cannata, Arturo Gonzalez-Izquierdo, Spiros Denaxas, Harry Hemingway, Ajay M. Shah, Derek M. Yellon, Theresa A. McDonagh
Summary: This study included 1172 patients with T2DM and prior MI and incident HF, finding that all classes of antidiabetic medication were associated with reduced risk of cardiovascular mortality and HF hospitalization.
Editorial Material
Cardiac & Cardiovascular Systems
Maryna V. Basalay, Derek M. Yellon, Sean M. Davidson
CARDIOVASCULAR DRUGS AND THERAPY
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Lucie Pearce, Richard D. Carr, Derek M. Yellon, Sean M. Davidson
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Gerd Heusch, Ioanna Andreadou, Robert Bell, Edoardo Bertero, Hans-Erik Botker, Sean M. Davidson, James Downey, Philip Eaton, Peter Ferdinandy, Bernard J. Gersh, Mauro Giacca, Derek J. Hausenloy, Borja Ibanez, Thomas Krieg, Christoph Maack, Rainer Schulz, Frank Sellke, Ajay M. Shah, Holger Thiele, Derek M. Yellon, Fabio Di Lisa
Summary: This review summarizes the roles of reactive oxygen species (ROS) in myocardial ischemia/reperfusion injury and cardioprotection. It emphasizes the need for cardioprotection beyond rapid reperfusion in acute myocardial infarction and discusses the pathomechanisms of myocardial ischemia/reperfusion, different modes of cell death in myocardial infarction, and interventions to protect the ischemic/reperfused myocardium. The second part focuses on ROS, providing an overview of molecular and cellular mechanisms involved in ischemia/reperfusion injury.
Article
Cardiac & Cardiovascular Systems
Roman Roy, Antonio Cannata, Mohammad Al-Agil, Emma Ferone, Antonio Jordan, Brian To-Dang, Matthew Sadler, Aamir Shamsi, Mohammad Albarjas, Susan Piper, Mauro Giacca, Ajay M. Shah, Theresa Mcdonagh, Daniel Bromage, Paul A. Scott
Summary: This study aimed to investigate the diagnostic accuracy of different approaches for the diagnosis of acute myocarditis (AM). The findings indicate that ICD-10 codes have poor accuracy in identifying AM cases and should be used with caution in clinical research. The selection criteria used to diagnose AM can have important implications for patient management and outcomes. Standardization of inclusion criteria for AM studies is necessary.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)
Article
Cardiac & Cardiovascular Systems
Derek M. Yellon, Siavash Beikoghli Kalkhoran, Sean M. Davidson
Summary: Ischaemic heart disease is a leading cause of death worldwide, and despite the development of several cardioprotective therapies, clinical translation has been disappointing. However, targeting the 'reperfusion injury salvage kinase' (RISK) pathway shows promise for cardioprotection. This pathway plays a crucial role in preventing mitochondrial permeability transition pore (MPTP) opening and cardiac cell death.
BASIC RESEARCH IN CARDIOLOGY
(2023)